Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Viridian Therapeutics, Inc. (VRDN)
USD19.17
+0.18 (+0.97%)
US NASDAQ Healthcare Biotechnology
Address
221 Crescent Street 2453
Waltham, MA, US
Waltham, MA, US
CEO
Stephen F. Mahoney
Website
viridiantherapeutics.com
IPO
2014-06-18
CIK 1590750 ISIN US92790C1045
Also trades on
London Stock Exchange · 0K1R.L (USD)
NASDAQ Capital Market · VRDN (USD)
Description
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Miragen | SGNL | 2016-12-02 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD19.17
+0.18 (+0.97%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.90
Float Shares
69.56M
Free Float %
82.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.55% | -2.05% | +15.05% | -40.17% | -40.57% | -44.73% | +31.10% | -26.59% | +2.02% | -87.79% | -99.16% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (16 ratings, all time)
Buy
Price Targets & DCF
Current price
19.17
Low
31.00
+61.7%
Consensus
40.71
+112.3%
Median
45.00
+134.7%
High
50.00
+160.8%
Ratings Trend (MoM)
94% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 13 | -1 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
33.33
+73.8%
|
| Last Quarter | 4 |
36.25
+89.1%
|
| Last Year | 14 |
41.07
+114.2%
|
| All Time | 33 |
30.92
+61.3%
|
Quality scores
Altman Z-Score
2.84
Grey zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+23,359.9% ★ Q1'26: +95.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+16.6% Q1'26: -18.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-451.1% Q1'26: -84,877.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-476.6% Q1'26: -82,389.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +619.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+24.9% Q1'26: +25.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.15× Q1'26: -0.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 8 EPS Ana. |
Dec 2027 11 Rev. Ana. 11 EPS Ana. |
Dec 2028 11 Rev. Ana. 3 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 5 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.54M
est: 2.44M (+4.0%)
|
3.34M
est: 3.96M (-15.7%)
|
4.00M
est: 4.26M (-6.0%)
|
8.39M
est: 9.29M (-9.7%)
|
4.46M
est: 4.32M (+3.4%)
|
1.05M
est: 866.7K (+21.2%)
|
2.96M
est: 3.00M (-1.3%)
|
1.77M
est: 2.13M (-16.7%)
|
314.0K
est: 288.0K (+9.0%)
|
302.0K
est: 317.3K (-4.8%)
|
70.85M
est: 85.43M (-17.1%)
|
56.39M
8.63M – 117.49M
-34.0% YoY
|
271.15M
171.24M – 471.74M
+380.8% YoY
|
579.88M
579.56M – 580.21M
+113.9% YoY
|
856.62M
434.50M – 1.72B
+47.7% YoY
|
1.13B
571.36M – 2.26B
+31.5% YoY
|
| EBITDA |
-11.00M
est: -2.44M (-350.9%)
|
-12.51M
est: -3.96M (-215.9%)
|
-25.82M
est: -4.26M (-506.1%)
|
-31.55M
est: -9.29M (-239.7%)
|
-40.75M
est: -4.32M (-844.3%)
|
-40.28M
est: -866.7K (-4,547.7%)
|
-79.29M
est: -3.00M (-2,541.2%)
|
-129.13M
est: -2.13M (-5,968.9%)
|
-235.37M
est: -288.0K (-81,624.0%)
|
-265.66M
est: -317.3K (-83,629.8%)
|
-337.19M
est: -85.43M (-294.7%)
|
-56.39M
-117.49M – -8.63M
+34.0% YoY
|
-271.15M
-471.74M – -171.24M
-380.8% YoY
|
-579.88M
-580.21M – -579.56M
-113.9% YoY
|
-856.62M
-1.72B – -434.50M
-47.7% YoY
|
-1.13B
-2.26B – -571.36M
-31.5% YoY
|
| EBIT |
-11.19M
est: -2.44M (-358.5%)
|
-12.58M
est: -3.96M (-217.7%)
|
-26.13M
est: -4.26M (-513.3%)
|
-31.83M
est: -9.29M (-242.7%)
|
-41.04M
est: -4.32M (-851.0%)
|
-40.52M
est: -866.7K (-4,575.3%)
|
-79.41M
est: -3.00M (-2,545.2%)
|
-129.39M
est: -2.13M (-5,980.8%)
|
-235.89M
est: -288.0K (-81,805.2%)
|
-266.90M
est: -317.3K (-84,020.6%)
|
-337.65M
est: -85.43M (-295.2%)
|
-56.39M
-117.49M – -8.63M
+34.0% YoY
|
-271.15M
-471.74M – -171.24M
-380.8% YoY
|
-579.88M
-580.21M – -579.56M
-113.9% YoY
|
-856.62M
-1.72B – -434.50M
-47.7% YoY
|
-1.13B
-2.26B – -571.36M
-31.5% YoY
|
| Net Income |
-11.33M
est: -22.68B (+100.0%)
|
-12.67M
est: -947.01M (+98.7%)
|
-26.51M
est: -1.37B (+98.1%)
|
-32.70M
est: -1.08B (+97.0%)
|
-41.87M
est: -1.16B (+96.4%)
|
-110.72M
est: -347.01M (+68.1%)
|
-79.41M
est: -365.52M (+78.3%)
|
-129.87M
est: -197.90M (+34.4%)
|
-237.73M
est: -228.06M (-4.2%)
|
-269.95M
est: -337.64M (+20.0%)
|
-342.60M
est: -303.27M (-13.0%)
|
-309.13M
-378.85M – -239.41M
-1.9% YoY
|
-267.81M
-292.86M – -65.89M
+13.4% YoY
|
-21.50M
-41.55M – -1.46M
+92.0% YoY
|
137.00M
49.24M – 316.38M
+737.1% YoY
|
257.80M
92.65M – 595.34M
+88.2% YoY
|
| SGA |
10.25M
est: 266.45M (-96.2%)
|
9.58M
est: 432.33M (-97.8%)
|
10.91M
est: 465.25M (-97.7%)
|
11.05M
est: 1.01B (-98.9%)
|
11.65M
est: 471.22M (-97.5%)
|
13.27M
est: 94.64M (-86.0%)
|
25.81M
est: 327.82M (-92.1%)
|
35.18M
est: 232.36M (-84.9%)
|
95.00M
est: 30.80M (+208.4%)
|
61.08M
est: 33.93M (+80.0%)
|
95.32M
est: 9.14B (-99.0%)
|
6.03B
923.09M – 12.56B
-34.0% YoY
|
29.00B
18.31B – 50.45B
+380.8% YoY
|
62.01B
61.98B – 62.05B
+113.9% YoY
|
91.61B
46.47B – 183.87B
+47.7% YoY
|
120.47B
61.10B – 241.79B
+31.5% YoY
|
| EPS |
-21.00
est: -334.13 (+93.7%)
|
-17.57
est: -13.95 (-25.9%)
|
-20.66
est: -20.21 (-2.2%)
|
-16.57
est: -15.93 (-4.0%)
|
-20.31
est: -17.13 (-18.6%)
|
-31.20
est: -5.11 (-510.4%)
|
-6.66
est: -5.38 (-23.7%)
|
-3.91
est: -3.56 (-9.9%)
|
-5.31
est: -4.18 (-27.2%)
|
-3.98
est: -4.00 (+0.5%)
|
-3.32
est: -3.53 (+6.0%)
|
-3.74
-4.47 – -2.82
-6.0% YoY
|
-2.29
-3.45 – -0.78
+38.9% YoY
|
-0.19
-0.49 – -0.02
+91.7% YoY
|
1.62
0.58 – 3.73
+946.2% YoY
|
3.04
1.09 – 7.02
+88.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-289.36M
OE per share TTM
-3.24
Owner's Yield
-15.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
20.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
95.96M
Insider transactions (90d)
0
Beneficial owners (>5%)
43
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Abigail P. Johnson | 7.63M | 14.50% | — | — | 7.63M | — | IN | Delaware | 2024-01-10 | ↗ |
| 2 | FMR LLC | 7.63M | 14.50% | 7.62M | — | 7.63M | — | HC | Delaware | 2024-01-10 | ↗ |
| 3 | Joseph Edelman | 4.02M | 6.70% | — | 4.02M | — | 4.02M | IN | Delaware | 2024-01-29 | ↗ |
| 4 | Perceptive Advisors LLC | 4.02M | 6.70% | — | 4.02M | — | 4.02M | IA | Delaware | 2024-01-29 | ↗ |
| 5 | Perceptive Life Sciences Master Fund, Ltd. | 4.02M | 6.70% | — | 4.02M | — | 4.02M | CO | Delaware | 2024-01-29 | ↗ |
| 6 | Venrock Opportunities Fund, L.P. | 2.82M | 5.20% | — | 2.82M | — | — | PN | Delaware | 2023-12-08 | ↗ |
| 7 | Venrock Opportunities Management, LLC | 2.82M | 5.20% | — | 2.82M | — | — | OO | Delaware | 2023-12-08 | ↗ |
| 8 | (1) BlackRock, Inc. | 2.76M | 6.90% | 2.71M | — | 2.76M | — | HC | Delaware | 2023-02-03 | ↗ |
| 9 | STATE STREET CORPORATION | 2.71M | 5.15% | — | 2.62M | — | 2.71M | HC | BOSTON, MASSACHUSETTS | 2024-01-24 | ↗ |
| 10 | Paradigm BioCapital Advisors LP | 2.31M | 5.40% | 2.31M | — | 2.31M | — | PN | United States America | 2023-05-11 | ↗ |
| 11 | Koh, Bong | 2.21M | 9.99% | — | 2.21M | — | — | IN | United States | 2022-02-14 | ↗ |
| 12 | L.P. | 2.21M | 9.99% | — | 2.21M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 13 | VHCP Co-Investment Holdings III, LLC | 2.21M | 9.99% | — | 2.21M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 14 | VHCP Management EG, LLC | 2.21M | 9.99% | — | 2.21M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 15 | VHCP Management III, LLC | 2.21M | 9.99% | — | 2.21M | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 16 | Venrock Healthcare Capital Partners EG, L.P. | 2.21M | 9.99% | — | 2.21M | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 17 | The Vanguard Group - 23-1945930 | 2.11M | 5.25% | — | 55.8K | 2.03M | 86.3K | IA | — | 2023-02-09 | ↗ |
| 18 | Bihua Chen | 1.44M | 6.28% | — | 1.44M | — | 1.44M | IN | United States | 2022-02-14 | ↗ |
| 19 | Cormorant Asset Management, LP | 1.44M | 6.28% | — | 1.44M | — | 1.44M | PN | Delaware | 2022-02-14 | ↗ |
| 20 | Israel A. Englander | 1.42M | 5.10% | — | 1.42M | — | 1.42M | IN | — | 2022-05-31 | ↗ |
| 21 | Millennium Group Management LLC | 1.42M | 5.10% | — | 1.42M | — | 1.42M | OO | — | 2022-05-31 | ↗ |
| 22 | Millennium Management LLC | 1.42M | 5.10% | — | 1.42M | — | 1.42M | OO | — | 2022-05-31 | ↗ |
| 23 | Cormorant Global Healthcare GP, LLC | 1.38M | 6.05% | — | 1.38M | — | 1.38M | OO | Delaware | 2022-02-14 | ↗ |
| 24 | Cormorant Global Healthcare Master Fund, LP | 1.38M | 6.05% | — | 1.38M | — | 1.38M | PN | Cayman Islands | 2022-02-14 | ↗ |
| 25 | Capital LP | 1.37M | 5.00% | — | 1.37M | — | 1.37M | IA | USA | 2022-05-19 | ↗ |
| 26 | Capital Master LP | 1.37M | 5.00% | — | 1.37M | — | 1.37M | OO | Islands | 2022-05-19 | ↗ |
| 27 | Dr. Senai Asefaw | 1.21M | 5.57% | 1.21M | — | 1.21M | — | IN | — | 2022-02-14 | ↗ |
| 28 | Paradigm BioCapital Advisors GP LLC | 1.21M | 5.57% | 1.21M | — | 1.21M | — | OO | — | 2022-02-14 | ↗ |
| 29 | D. E. Shaw & Co., L.L.C. | 764.6K | 3.50% | — | 764.6K | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 30 | D. E. Shaw & Co., L.P. | 764.6K | 3.50% | — | 764.6K | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 31 | David E. Shaw | 764.6K | 3.50% | — | 764.6K | — | — | IN | United States | 2022-02-14 | ↗ |
| 32 | Paradigm BioCapital International Fund Ltd. | 706.0K | 3.25% | 706.0K | — | 706.0K | — | CO | — | 2022-02-14 | ↗ |
| 33 | D. E. Shaw Valence Portfolios, L.L.C. | 583.7K | 2.70% | — | 583.7K | — | — | OO | Delaware | 2022-02-14 | ↗ |
| 34 | Point72 Asset Management, L.P. | 472.9K | 4.00% | — | 472.9K | — | 472.9K | PN | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 35 | Point72 Capital Advisors, Inc. | 472.9K | 4.00% | — | 472.9K | — | 472.9K | CO | Citizenship or place of organization Delaware | 2022-02-14 | ↗ |
| 36 | Steven A. Cohen | 472.9K | 4.00% | — | 472.9K | — | 472.9K | IN | Citizenship or place of organization United States | 2022-02-14 | ↗ |
| 37 | Frazier Life Sciences Public Fund, L.P. | 300.0K | 1.10% | — | 300.0K | — | 300.0K | PN | United States Citizen | 2022-08-12 | ↗ |
| 38 | 2. | 10.00 | 4.30% | — | 939.8K | — | — | HC, PN | — | 2022-02-14 | ↗ |
| 39 | Logos Global Management LP | — | 11.00% | — | — | — | — | IA, PN | United States | 2022-02-14 | ↗ |
| 40 | Peter Kolchinsky | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
| 41 | RA Capital Healthcare Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2022-02-14 | ↗ |
| 42 | RA Capital Management, L.P. | — | 0.00% | — | — | — | — | IA, PN | Delaware | 2022-02-14 | ↗ |
| 43 | Rajeev Shah | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
44
-189 vs prev Q
New positions
9
Closed positions
193
Increased
20
Reduced
17
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 858.6K +858.6K (+100.0%) | 26.72B +26.7B (+100.0%) | 1.05% +1.050 pp | 7.89% +7.886 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 2 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 154.7K +154.7K (+100.0%) | 4.82B +4.8B (+100.0%) | 0.19% +0.189 pp | 0.01% +0.007 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 3 | FMR LLC | 14.38M +2.1M (+17.4%) | 447.64M +183.3M (+69.3%) | 17.59% +2.576 pp | 0.02% +0.009 pp | USD22.34 +39.3% | 15 qtrs — |
| 4 | BLACKROCK, INC. | 6.43M +1.0M (+18.5%) | 200.16M +83.0M (+70.9%) | 7.86% +1.211 pp | 0.00% +0.001 pp | USD23.55 +32.1% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 5.61M +1.3M (+29.6%) | 174.65M +81.2M (+86.8%) | 6.86% +1.553 pp | 0.00% +0.001 pp | USD22.80 +36.5% | 20 qtrs — |
| 6 | BELLEVUE GROUP AG | 4.36M +4.4M (+100.0%) | 135.64M +135.6M (+100.0%) | 5.33% +5.329 pp | 2.57% +2.570 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 7 | FAIRMOUNT FUNDS MANAGEMENT LLC | 3.91M +454.5K (+13.1%) | 121.82M +47.2M (+63.2%) | 4.79% +0.546 pp | 9.27% +2.554 pp | USD21.26 +46.4% | 20 qtrs — |
| 8 | VR ADVISER, LLC | 3.88M +— (+0.0%) | 120.83M +37.0M (+44.2%) | 4.75% -0.011 pp | 5.97% +1.252 pp | USD22.00 +41.5% | 21 qtrs — |
| 9 | STATE STREET CORP | 3.47M +912.4K (+35.7%) | 107.88M +52.8M (+95.7%) | 4.24% +1.108 pp | 0.00% +0.002 pp | USD23.01 +35.2% | 19 qtrs — |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.44M +1.0M (+42.2%) | 107.04M +54.9M (+105.1%) | 4.21% +1.242 pp | 0.01% +0.006 pp | USD20.70 +50.3% | 14 qtrs — |
| 11 | PERCEPTIVE ADVISORS LLC | 3.04M +1.6M (+108.1%) | 94.69M +63.1M (+200.0%) | 3.72% +1.928 pp | 1.69% +0.777 pp | USD26.39 +17.9% | 19 qtrs — |
| 12 | DEEP TRACK CAPITAL, LP | 2.52M -2.9M (-53.1%) | 78.57M -37.5M (-32.3%) | 3.09% -3.507 pp | 1.40% -1.839 pp | USD17.20 +80.9% | 17 qtrs — |
| 13 | NOVO HOLDINGS A/S | 2.38M +— (+0.0%) | 74.07M +22.7M (+44.2%) | 2.91% -0.007 pp | 5.75% +2.442 pp | USD16.47 +88.9% | 8 qtrs — |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.99M +226.0K (+12.8%) | 62.01M +23.9M (+62.7%) | 2.44% +0.271 pp | 0.00% +0.001 pp | USD19.83 +56.9% | 20 qtrs — |
| 15 | BAKER BROS. ADVISORS LP | 1.97M +227.3K (+13.0%) | 61.36M +23.7M (+63.0%) | 2.41% +0.273 pp | 0.36% +0.087 pp | USD15.96 +95.0% | 3 qtrs — |
| 16 | WELLINGTON MANAGEMENT GROUP LLP | 1.97M +848.9K (+75.6%) | 61.35M +37.1M (+153.3%) | 2.41% +1.035 pp | 0.01% +0.007 pp | USD25.55 +21.8% | 13 qtrs — |
| 17 | TANG CAPITAL MANAGEMENT LLC | 1.79M -1.1M (-36.9%) | 55.79M -5.6M (-9.1%) | 2.19% -1.292 pp | 2.76% +0.394 pp | USD17.47 +78.1% | 15 qtrs — |
| 18 | EVERSEPT PARTNERS, LP | 1.78M -142.1K (-7.4%) | 55.46M +13.9M (+33.6%) | 2.18% -0.179 pp | 2.79% -0.067 pp | USD14.65 +112.4% | 10 qtrs — |
| 19 | FISHER ASSET MANAGEMENT, LLC | 1.78M +579.1K (+48.2%) | 55.40M +29.5M (+113.7%) | 2.18% +0.705 pp | 0.02% +0.010 pp | USD23.71 +31.3% | 8 qtrs — |
| 20 | MORGAN STANLEY | 1.74M +1.5M (+805.6%) | 54.09M +50.0M (+1,205.9%) | 2.13% +1.890 pp | 0.00% +0.003 pp | USD30.06 +3.5% | 19 qtrs — |
| 21 | AVORO CAPITAL ADVISORS LLC | 1.50M +1.5M (+100.0%) | 46.68M +46.7M (+100.0%) | 1.83% +1.834 pp | 0.45% +0.449 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 22 | LOOMIS SAYLES & CO L P | 1.48M -69.2K (-4.5%) | 46.09M +12.6M (+37.8%) | 1.81% -0.089 pp | 0.06% +0.016 pp | USD19.50 +59.6% | 5 qtrs — |
| 23 | KYNAM CAPITAL MANAGEMENT, LP | 1.47M -3.0M (-66.8%) | 45.76M -49.8M (-52.1%) | 1.80% -3.629 pp | 2.92% -4.191 pp | USD16.09 +93.4% | 17 qtrs — |
| 24 | PARADIGM BIOCAPITAL ADVISORS LP | 1.44M -1.2M (-44.7%) | 44.91M -11.4M (-20.2%) | 1.76% -1.434 pp | 1.15% -0.455 pp | USD17.79 +74.9% | 17 qtrs — |
| 25 | ALLIANCEBERNSTEIN L.P. | 1.41M -445.3K (-23.9%) | 44.01M +3.9M (+9.7%) | 1.73% -0.550 pp | 0.01% +0.001 pp | USD23.17 +34.3% | 15 qtrs — |
| 26 | MARSHALL WACE, LLP | 1.38M +506.6K (+58.3%) | 42.81M +24.1M (+128.2%) | 1.68% +0.617 pp | 0.04% +0.020 pp | USD20.01 +55.5% | 17 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 1.26M +499.5K (+65.3%) | 39.34M +22.8M (+138.4%) | 1.55% +0.609 pp | 0.00% +0.003 pp | USD22.13 +40.6% | 16 qtrs — |
| 28 | JENNISON ASSOCIATES LLC | 1.15M +1.2M (+100.0%) | 35.91M +35.9M (+100.0%) | 1.41% +1.411 pp | 0.02% +0.022 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 29 | WOODLINE PARTNERS LP | 1.12M +300.4K (+36.8%) | 34.73M +17.1M (+97.3%) | 1.36% +0.365 pp | 0.13% +0.052 pp | USD23.03 +35.1% | 8 qtrs — |
| 30 | JPMORGAN CHASE & CO | 1.01M +701.1K (+226.8%) | 31.44M +24.8M (+371.3%) | 1.24% +0.856 pp | 0.00% +0.002 pp | USD27.46 +13.3% | 17 qtrs — |
| 31 | D. E. SHAW & CO., INC. | 1.00M +1.0M (+100.0%) | 31.14M +31.1M (+100.0%) | 1.22% +1.224 pp | 0.02% +0.017 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 32 | BANK OF AMERICA CORP /DE/ | 990.1K +744.4K (+302.9%) | 30.81M +25.5M (+481.0%) | 1.21% +0.909 pp | 0.00% +0.002 pp | USD28.15 +10.6% | 18 qtrs — |
| 33 | VIVO CAPITAL, LLC | 982.6K +— (+0.0%) | 30.58M +9.4M (+44.2%) | 1.20% -0.003 pp | 1.98% +0.270 pp | USD17.46 +78.2% | 18 qtrs — |
| 34 | PICTET ASSET MANAGEMENT HOLDING SA | 922.8K -126.6K (-12.1%) | 28.72M +6.1M (+26.8%) | 1.13% -0.158 pp | 0.03% +0.006 pp | USD16.08 +93.5% | 10 qtrs — |
| 35 | RICE HALL JAMES & ASSOCIATES, LLC | 884.5K +32.9K (+3.9%) | 27.53M +9.1M (+49.8%) | 1.08% +0.038 pp | 1.52% +0.513 pp | USD17.64 +76.4% | 5 qtrs — |
| 36 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 790.0K -430.1K (-35.3%) | 24.59M -1.7M (-6.6%) | 0.97% -0.529 pp | 0.04% -0.005 pp | USD21.74 +43.1% | 6 qtrs — |
| 37 | PARKMAN HEALTHCARE PARTNERS LLC | 788.1K -366.4K (-31.7%) | 24.52M -388.9K (-1.6%) | 0.96% -0.451 pp | 2.33% -0.264 pp | USD19.38 +60.6% | 6 qtrs — |
| 38 | CANDRIAM S.C.A. | 785.1K -75.1K (-8.7%) | 24.43M +5.9M (+31.6%) | 0.96% -0.094 pp | 0.12% +0.025 pp | USD14.51 +114.5% | 8 qtrs — |
| 39 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 749.0K +153.6K (+25.8%) | 23.31M +10.5M (+81.4%) | 0.92% +0.186 pp | 0.00% +0.002 pp | USD20.18 +54.2% | 15 qtrs — |
| 40 | NUVEEN, LLC | 742.3K +580.5K (+358.6%) | 23.10M +19.6M (+561.3%) | 0.91% +0.709 pp | 0.01% +0.005 pp | USD27.27 +14.1% | 4 qtrs — |
| 41 | 5AM VENTURE MANAGEMENT, LLC | 736.6K +— (+0.0%) | 22.92M +7.0M (+44.2%) | 0.90% -0.002 pp | 7.21% +1.385 pp | USD19.24 +61.7% | 14 qtrs — |
| 42 | FIRST TURN MANAGEMENT, LLC | 690.5K +690.5K (+100.0%) | 21.49M +21.5M (+100.0%) | 0.84% +0.844 pp | 2.46% +2.455 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 43 | CITADEL ADVISORS LLC | 679.7K +602.3K (+778.5%) | 21.15M +19.5M (+1,166.8%) | 0.83% +0.736 pp | 0.00% +0.003 pp | USD29.28 +6.3% | 17 qtrs — |
| 44 | NORTHERN TRUST CORP | 668.4K +47.6K (+7.7%) | 20.80M +7.4M (+55.3%) | 0.82% +0.056 pp | 0.00% +0.001 pp | USD19.93 +56.1% | 19 qtrs — |
| 45 | DIMENSIONAL FUND ADVISORS LP | 555.6K -83.2K (-13.0%) | 17.29M +3.5M (+25.4%) | 0.68% -0.104 pp | 0.00% +0.001 pp | USD15.80 +97.0% | 15 qtrs — |
| 46 | BNP PARIBAS ARBITRAGE, SNC | 517.4K +275.1K (+113.5%) | 16.10M +10.9M (+207.9%) | 0.63% +0.336 pp | 0.01% +0.005 pp | USD25.25 +23.2% | 5 qtrs — |
| 47 | BALYASNY ASSET MANAGEMENT L.P. | 503.9K +301.0K (+148.4%) | 15.68M +11.3M (+258.3%) | 0.62% +0.368 pp | 0.02% +0.014 pp | USD27.28 +14.1% | 2 qtrs — |
| 48 | DEUTSCHE BANK AG\ | 479.8K -457.7K (-48.8%) | 14.93M -5.3M (-26.2%) | 0.59% -0.562 pp | 0.00% -0.002 pp | USD21.97 +41.6% | 15 qtrs — |
| 49 | MILLENNIUM MANAGEMENT LLC | 460.1K +323.8K (+237.6%) | 14.32M +11.4M (+386.9%) | 0.56% +0.396 pp | 0.01% +0.005 pp | USD28.06 +10.9% | 20 qtrs — |
| 50 | ROSALIND ADVISORS, INC. | 450.0K -150.0K (-25.0%) | 14.00M +1.1M (+8.2%) | 0.55% -0.185 pp | 4.92% +0.496 pp | USD13.56 +129.5% | 4 qtrs — |
| 51 | ALGERT GLOBAL LLC | 425.0K +425.0K (+100.0%) | 13.23M +13.2M (+100.0%) | 0.52% +0.520 pp | 0.21% +0.206 pp | USD31.12 +0.0% | 8 qtrs — |
| 52 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 423.3K +— (+0.0%) | 13.17M +4.0M (+44.2%) | 0.52% -0.001 pp | 1.17% +0.463 pp | USD22.75 +36.8% | 6 qtrs — |
| 53 | FEDERATED HERMES, INC. | 416.4K +416.2K (+315,322.7%) | 12.96M +13.0M (+454,693.3%) | 0.51% +0.509 pp | 0.02% +0.022 pp | USD31.11 +0.0% | 3 qtrs — |
| 54 | HIGHVISTA STRATEGIES LLC | 372.5K -96.9K (-20.6%) | 11.59M +1.5M (+14.4%) | 0.46% -0.120 pp | 2.99% +0.503 pp | USD16.17 +92.5% | 16 qtrs — |
| 55 | SILVERARC CAPITAL MANAGEMENT, LLC | 348.6K +89.1K (+34.3%) | 10.85M +5.2M (+93.7%) | 0.43% +0.108 pp | 1.51% +0.751 pp | USD24.02 +29.6% | 2 qtrs — |
| 56 | VOLEON CAPITAL MANAGEMENT LP | 345.7K +345.7K (+100.0%) | 10.76M +10.8M (+100.0%) | 0.42% +0.423 pp | 0.23% +0.231 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 57 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 341.3K +341.3K (+100.0%) | 10.62M +10.6M (+100.0%) | 0.42% +0.417 pp | 0.01% +0.006 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 58 | PANAGORA ASSET MANAGEMENT INC | 324.7K -53.0K (-14.0%) | 10.11M +2.0M (+24.0%) | 0.40% -0.066 pp | 0.04% +0.003 pp | USD19.40 +60.4% | 6 qtrs — |
| 59 | RAYMOND JAMES FINANCIAL INC | 303.8K -9.0K (-2.9%) | 9.42M +2.7M (+39.6%) | 0.37% -0.012 pp | 0.00% +0.001 pp | USD18.88 +64.8% | 5 qtrs — |
| 60 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 286.3K +286.3K (+100.0%) | 8.91M +8.9M (+100.0%) | 0.35% +0.350 pp | 0.04% +0.036 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 61 | PROPEL BIO MANAGEMENT, LLC | 282.5K +192.5K (+213.9%) | 8.79M +6.9M (+352.7%) | 0.35% +0.235 pp | 7.51% +5.563 pp | USD28.08 +10.8% | 2 qtrs — |
| 62 | JANE STREET GROUP, LLC | 279.6K +244.2K (+689.5%) | 8.70M +7.9M (+1,038.6%) | 0.34% +0.299 pp | 0.00% +0.001 pp | USD29.79 +4.5% | 12 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 254.3K +254.3K (+100.0%) | 7.91M +7.9M (+100.0%) | 0.31% +0.311 pp | 0.01% +0.009 pp | USD31.12 +0.0% | 6 qtrs — |
| 64 | AFFINITY ASSET ADVISORS, LLC | 250.0K +— (+0.0%) | 7.78M +2.4M (+44.2%) | 0.31% -0.001 pp | 0.44% -0.027 pp | USD16.16 +92.6% | 9 qtrs — |
| 65 | BARCLAYS PLC | 244.3K +118.9K (+94.8%) | 7.60M +4.7M (+166.5%) | 0.30% +0.145 pp | 0.00% +0.001 pp | USD24.49 +27.1% | 16 qtrs — |
| 66 | VICTORY CAPITAL MANAGEMENT INC | 226.8K -205.6K (-47.5%) | 7.06M -2.3M (-24.4%) | 0.28% -0.253 pp | 0.00% -0.002 pp | USD17.63 +76.5% | 5 qtrs — |
| 67 | BANK OF NEW YORK MELLON CORP | 215.9K +18.7K (+9.5%) | 6.72M +2.5M (+57.9%) | 0.26% +0.022 pp | 0.00% +0.000 pp | USD19.52 +59.4% | 15 qtrs — |
| 68 | SCHONFELD STRATEGIC ADVISORS LLC | 217.4K +159.5K (+275.4%) | 6.56M +5.5M (+492.3%) | 0.27% +0.195 pp | 0.03% +0.023 pp | USD27.81 +11.9% | 14 qtrs — |
| 69 | YIHENG CAPITAL MANAGEMENT, L.P. | 208.7K -291.5K (-58.3%) | 6.50M -4.3M (-39.8%) | 0.26% -0.358 pp | 1.31% -0.278 pp | USD25.75 +20.9% | 14 qtrs — |
| 70 | RUSSELL INVESTMENTS GROUP, LTD. | 193.5K +58.5K (+43.3%) | 6.02M +3.1M (+106.7%) | 0.24% +0.071 pp | 0.01% +0.003 pp | USD23.42 +32.9% | 14 qtrs — |
| 71 | INVESCO LTD. | 183.5K +102.7K (+127.1%) | 5.71M +4.0M (+227.5%) | 0.22% +0.125 pp | 0.00% +0.001 pp | USD25.39 +22.6% | 15 qtrs — |
| 72 | PRINCIPAL FINANCIAL GROUP INC | 175.9K -37.4K (-17.5%) | 5.47M +871.3K (+18.9%) | 0.22% -0.046 pp | 0.00% +0.001 pp | USD21.54 +44.5% | 13 qtrs — |
| 73 | PRIVIUM FUND MANAGEMENT B.V. | 173.5K +173.5K (+100.0%) | 5.40M +5.4M (+100.0%) | 0.21% +0.212 pp | 0.99% +0.994 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 74 | KOPP FAMILY OFFICE, LLC | 173.2K -20.7K (-10.7%) | 5.39M +1.2M (+28.8%) | 0.21% -0.026 pp | 3.44% +0.717 pp | USD25.93 +20.0% | 13 qtrs — |
| 75 | HENNION & WALSH ASSET MANAGEMENT, INC. | 169.2K +14.8K (+9.6%) | 5.26M +1.9M (+58.1%) | 0.21% +0.018 pp | 0.18% +0.061 pp | USD19.07 +63.2% | 11 qtrs — |
| 76 | DRIEHAUS CAPITAL MANAGEMENT LLC | 167.9K -176.2K (-51.2%) | 5.23M -2.2M (-29.6%) | 0.21% -0.216 pp | 0.04% -0.018 pp | USD22.75 +36.8% | 6 qtrs — |
| 77 | UBS GROUP AG | 164.8K -282.9K (-63.2%) | 5.13M -4.5M (-46.9%) | 0.20% -0.347 pp | 0.00% -0.001 pp | USD18.97 +64.0% | 18 qtrs — |
| 78 | STEMPOINT CAPITAL LP | 154.3K +154.3K (+100.0%) | 4.80M +4.8M (+100.0%) | 0.19% +0.189 pp | 0.82% +0.824 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 79 | HUDSON BAY CAPITAL MANAGEMENT LP | 151.5K -23.8K (-13.6%) | 4.71M +931.6K (+24.6%) | 0.19% -0.030 pp | 0.02% +0.003 pp | USD16.40 +89.8% | 3 qtrs — |
| 80 | MOORE CAPITAL MANAGEMENT, LP | 150.0K +150.0K (+100.0%) | 4.67M +4.7M (+100.0%) | 0.18% +0.183 pp | 0.07% +0.067 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 81 | WELLS FARGO & COMPANY/MN | 147.3K +41.4K (+39.1%) | 4.58M +2.3M (+100.6%) | 0.18% +0.050 pp | 0.00% +0.000 pp | USD23.29 +33.6% | 20 qtrs — |
| 82 | KNOTT DAVID M JR | 145.0K +28.4K (+24.4%) | 4.51M +2.0M (+79.4%) | 0.18% +0.034 pp | 2.09% +1.075 pp | USD19.53 +59.3% | 5 qtrs — |
| 83 | UBS ASSET MANAGEMENT AMERICAS INC | 139.4K +380.0 (+0.3%) | 4.34M +1.3M (+44.6%) | 0.17% +0.000 pp | 0.00% +0.000 pp | USD16.85 +84.7% | 13 qtrs — |
| 84 | CENTERBOOK PARTNERS LP | 136.7K +136.7K (+100.0%) | 4.25M +4.3M (+100.0%) | 0.17% +0.167 pp | 0.21% +0.208 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 85 | QUBE RESEARCH & TECHNOLOGIES LTD | 129.5K +129.5K (+100.0%) | 4.03M +4.0M (+100.0%) | 0.16% +0.158 pp | 0.00% +0.004 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 86 | SWISS NATIONAL BANK | 128.6K +17.9K (+16.2%) | 4.00M +1.6M (+67.5%) | 0.16% +0.022 pp | 0.00% +0.001 pp | USD19.24 +61.7% | 15 qtrs — |
| 87 | NORGES BANK | 122.8K +122.8K (+100.0%) | 3.82M +3.8M (+100.0%) | 0.15% +0.150 pp | 0.00% +0.000 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 88 | FIRST TRUST ADVISORS LP | 119.9K +119.9K (+100.0%) | 3.73M +3.7M (+100.0%) | 0.15% +0.147 pp | 0.00% +0.003 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 89 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 116.5K +78.9K (+209.6%) | 3.63M +2.8M (+346.4%) | 0.14% +0.096 pp | 0.00% +0.000 pp | USD27.24 +14.2% | 16 qtrs — |
| 90 | TD ASSET MANAGEMENT INC | 114.0K +35.2K (+44.7%) | 3.55M +1.8M (+108.6%) | 0.14% +0.043 pp | 0.00% +0.002 pp | USD20.58 +51.2% | 5 qtrs — |
| 91 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 112.7K +29.2K (+34.9%) | 3.50M +1.7M (+94.2%) | 0.14% +0.035 pp | 0.00% +0.001 pp | USD20.39 +52.6% | 15 qtrs — |
| 92 | SIMPLIFY ASSET MANAGEMENT INC. | 103.5K +53.5K (+107.1%) | 3.22M +2.1M (+198.6%) | 0.13% +0.065 pp | 0.05% +0.033 pp | USD26.51 +17.4% | 2 qtrs — |
| 93 | SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 101.1K +— (+0.0%) | 3.15M +964.3K (+44.2%) | 0.12% 0.000 pp | 0.11% +0.022 pp | USD13.48 +130.9% | 4 qtrs — |
| 94 | SEVEN GRAND MANAGERS, LLC | 100.0K +100.0K (+100.0%) | 3.11M +3.1M (+100.0%) | 0.12% +0.122 pp | 0.24% +0.237 pp | USD31.12 +0.0% | 1 qtrs NEW |
| 95 | RAFFERTY ASSET MANAGEMENT, LLC | 99.8K +31.7K (+46.6%) | 3.10M +1.6M (+111.3%) | 0.12% +0.039 pp | 0.01% +0.006 pp | USD23.49 +32.5% | 14 qtrs — |
| 96 | RHUMBLINE ADVISERS | 97.5K -6.9K (-6.6%) | 3.03M +780.6K (+34.7%) | 0.12% -0.009 pp | 0.00% +0.001 pp | USD16.95 +83.6% | 15 qtrs — |
| 97 | MOODY ALDRICH PARTNERS LLC | 96.2K +22.1K (+29.8%) | 2.99M +1.4M (+87.2%) | 0.12% +0.027 pp | 0.56% +0.255 pp | USD20.51 +51.7% | 5 qtrs — |
| 98 | MERCK & CO., INC. | 93.4K +— (+0.0%) | 2.91M +891.2K (+44.2%) | 0.11% 0.000 pp | 1.05% +0.168 pp | USD19.17 +62.3% | 5 qtrs — |
| 99 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 92.7K +78.3K (+543.1%) | 2.88M +2.6M (+827.5%) | 0.11% +0.096 pp | 0.02% +0.019 pp | USD29.64 +5.0% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 104 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | F/M Emerald Life Sciences Innovation ETF LFSC | 2.13% | 1.59M | 0.54% |
| 2 | Fidelity Disruptive Medicine ETF FMED | 1.28% | 595.3K | 0.50% |
| 3 | ALPS Medical Breakthroughs ETF SBIO | 1.11% | 2.37M | 0.50% |
| 4 | Virtus Biotech Clinical Trials ETF BBC | 0.74% | 427.7K | 0.65% |
| 5 | Global X - S&P Biotech ETF CURE.AX | 0.72% | 257.8K | 0.45% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.72% | 77.66M | 0.35% |
| 7 | iShares Micro-Cap ETF IWC | 0.40% | 5.97M | 0.60% |
| 8 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.24% | 2.78M | 0.40% |
| 9 | Pacer WealthShield ETF PWS | 0.15% | 35.9K | 0.60% |
| 10 | T. Rowe Price Small-Mid Cap ETF TMSL | 0.13% | 3.67M | 0.55% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.75
Bullish
Ratio by volume
3.00
Bullish
Buys
14
Sells
8
Shares acquired
1.30M
Shares disposed
53.8K
Cash buys
—
Cash sales
—
Net activity
+1,250,270
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | Tousignant Jennifer | Officer | F-InKind | D | Common Stock | 1,724 | 29.32 | 50.5K | 3,445 | D | ↗ |
| 2026-03-03 | Mahoney Stephen F. | Officer | F-InKind | D | Common Stock | 7,627 | 29.32 | 223.6K | 33,130 | D | ↗ |
| 2026-03-03 | Harmon Seth | Officer | F-InKind | D | Common Stock | 2,031 | 30.19 | 61.3K | 7,850 | D | ↗ |
| 2026-03-03 | Beetham Thomas W. | Officer | F-InKind | D | Common Stock | 3,138 | 29.32 | 92.0K | 13,271 | D | ↗ |
| 2026-03-02 | Tripuraneni Radhika | Officer | A-Award | A | Restricted Stock Units | 19,150 | 0.00 | — | 19,150 | D | ↗ |
| 2026-03-02 | Tousignant Jennifer | Officer | A-Award | A | Restricted Stock Units | 23,850 | 0.00 | — | 23,850 | D | ↗ |
| 2026-03-02 | Mahoney Stephen F. | Officer | A-Award | A | Stock Option (Right to Buy) | 559,600 | 30.25 | 16.93M | 559,600 | D | ↗ |
| 2026-03-02 | Harmon Seth | Officer | A-Award | A | Stock Option (Right to Buy) | 102,850 | 30.25 | 3.11M | 102,850 | D | ↗ |
| 2026-03-02 | Beetham Thomas W. | Officer | A-Award | A | Stock Option (Right to Buy) | 176,550 | 30.25 | 5.34M | 176,550 | D | ↗ |
| 2025-12-31 | Tousignant Jennifer | Officer | S-Sale | D | Common Stock | 2,272 | 31.16 | 70.8K | 0 | D | ↗ |
| 2025-10-23 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 454,545 | 22.00 | 10.00M | 3,914,458 | I | ↗ |
| 2025-07-01 | Moses Jennifer K. | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | D | ↗ |
| 2025-07-01 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | D | ↗ |
| 2025-07-01 | Kiselak Tomas | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | I | ↗ |
| 2025-07-01 | Gheuens Sarah | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | D | ↗ |
| 2025-07-01 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | I | ↗ |
| 2025-07-01 | Ajer Jeffrey Robert | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 14.47 | 303.9K | 21,000 | D | ↗ |
| 2025-06-10 | Fairmount Funds Management LLC | Director / 10% Owner | M-Exempt | A | Common Stock | 12,500 | 12.31 | 153.9K | 3,459,913 | I | ↗ |
| 2025-06-09 | Fairmount Funds Management LLC | Director / 10% Owner | M-Exempt | D | Stock Option (Right to Buy) | 1,600 | 7.80 | 12.5K | 0 | I | ↗ |
| 2025-04-07 | Ajer Jeffrey Robert | Director | A-Award | A | Stock Option (Right to Buy) | 42,000 | 11.78 | 494.8K | 42,000 | D | ↗ |
| 2025-03-10 | Tripuraneni Radhika | Officer | A-Award | A | Stock Option (Right to Buy) | 310,700 | 15.58 | 4.84M | 310,700 | D | ↗ |
| 2025-03-10 | CAIN CHRISTOPHER W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-03 | Tousignant Jennifer | Officer | A-Award | A | Stock Option (Right to Buy) | 124,072 | 14.41 | 1.79M | 124,072 | D | ↗ |
| 2025-03-03 | Mahoney Stephen F. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 440,565 | 14.41 | 6.35M | 440,565 | D | ↗ |
| 2025-03-03 | Harmon Seth | Officer | A-Award | A | Stock Option (Right to Buy) | 150,407 | 14.41 | 2.17M | 150,407 | D | ↗ |
| 2025-03-03 | Beetham Thomas W. | Officer | A-Award | A | Restricted Stock Units | 37,636 | 0.00 | — | 37,636 | D | ↗ |
| 2024-09-27 | Mahoney Stephen F. | Director / Officer | P-Purchase | A | Common Stock | 21,400 | 23.33 | 499.3K | 21,400 | D | ↗ |
| 2024-09-27 | Beetham Thomas W. | Officer | P-Purchase | A | Common Stock | 5,000 | 23.41 | 117.1K | 6,000 | D | ↗ |
| 2024-09-13 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 1,600,000 | 18.75 | 30.00M | 3,445,813 | — | ↗ |
| 2024-06-26 | Moses Jennifer K. | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 12.31 | 258.5K | 21,000 | — | ↗ |
| 2024-06-26 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 12.31 | 258.5K | 21,000 | — | ↗ |
| 2024-06-26 | Kiselak Tomas | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 12.31 | 258.5K | 21,000 | — | ↗ |
| 2024-06-26 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 12.31 | 258.5K | 21,000 | — | ↗ |
| 2024-06-26 | Gheuens Sarah | Director | A-Award | A | Stock Option (Right to Buy) | 21,000 | 12.31 | 258.5K | 21,000 | — | ↗ |
| 2024-03-28 | Fairmount Funds Management LLC | Director / 10% Owner | J-Other | A | Common Stock | 5,859 | 0.00 | — | 1,845,813 | — | ↗ |
| 2024-02-12 | Tousignant Jennifer | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-05 | Ciulla Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 18.70 | 935.0K | 50,000 | — | ↗ |
| 2024-01-22 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 476,190 | 21.00 | 10.00M | 1,839,954 | — | ↗ |
| 2024-01-03 | Ciulla Thomas | Officer | — | D | Common Stock | 0 | 0.00 | — | 762 | — | ↗ |
| 2023-11-10 | Harmon Seth | Officer | A-Award | A | Stock Option (Right to Buy) | 270,000 | 13.76 | 3.72M | 270,000 | — | ↗ |
| 2023-10-30 | Mahoney Stephen F. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,259,400 | 13.02 | 16.40M | 1,259,400 | — | ↗ |
| 2023-10-30 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Series B Non-Voting Convertible Preferred Stock | 48,463 | 0.00 | — | 48,463 | — | ↗ |
| 2023-10-30 | Beetham Thomas W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-21 | Gheuens Sarah | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 15.74 | 629.6K | 40,000 | — | ↗ |
| 2023-09-12 | Harmon Seth | Officer | — | D | Stock Option (Right to Buy) | 175,000 | 24.50 | 4.29M | 0 | — | ↗ |
| 2023-06-16 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 28 | 23.03 | 644.84 | 37,453 | — | ↗ |
| 2023-06-15 | Meisner Lara | Officer | S-Sale | D | Common Stock | 2,269 | 28.02 | 63.6K | 29,971 | — | ↗ |
| 2023-06-14 | Moses Jennifer K. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 27.67 | 553.4K | 20,000 | — | ↗ |
| 2023-06-14 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 27.67 | 553.4K | 20,000 | — | ↗ |
| 2023-06-14 | Kiselak Tomas | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 27.67 | 553.4K | 20,000 | — | ↗ |
| 2023-06-14 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 27.67 | 553.4K | 20,000 | — | ↗ |
| 2023-06-06 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,126 | 18.51 | 94.9K | 84,375 | — | ↗ |
| 2023-06-05 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 499 | 18.51 | 9.2K | 89,501 | — | ↗ |
| 2023-06-02 | Meisner Lara | Officer | S-Sale | D | Common Stock | 1,875 | 24.21 | 45.4K | 29,971 | — | ↗ |
| 2023-04-12 | Myers Scott Dunseth | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 25.37 | 101.5K | 259,500 | — | ↗ |
| 2023-03-13 | Myers Scott Dunseth | — | P-Purchase | A | Common Stock | 5,500 | 29.15 | 160.3K | 255,500 | — | ↗ |
| 2023-03-09 | Meisner Lara | Officer | S-Sale | D | Common Stock | 29,971 | 29.07 | 871.3K | 0 | — | ↗ |
| 2023-02-08 | Melvin Carrie | Officer | A-Award | A | Stock Option (Right to Buy) | 54,000 | 34.20 | 1.85M | 54,000 | — | ↗ |
| 2023-02-08 | Meisner Lara | Officer | A-Award | A | Stock Option (Right to Buy) | 108,000 | 34.20 | 3.69M | 108,000 | — | ↗ |
| 2023-02-08 | Katz Barrett | Officer | A-Award | A | Stock Option (Right to Buy) | 108,000 | 34.20 | 3.69M | 108,000 | — | ↗ |
| 2023-02-08 | Humer Kristian | Officer | A-Award | A | Stock Option (Right to Buy) | 108,000 | 34.20 | 3.69M | 108,000 | — | ↗ |
| 2023-02-06 | Myers Scott Dunseth | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,000,000 | 35.80 | 35.80M | 1,000,000 | — | ↗ |
| 2023-02-02 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 50,000 | 36.80 | 1.84M | 480,905 | — | ↗ |
| 2023-01-23 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,971 | 0.00 | — | 39,750 | — | ↗ |
| 2023-01-17 | Katz Barrett | Officer | M-Exempt | D | Stock Option (Right to Buy) | 24,853 | 0.00 | — | 267,000 | — | ↗ |
| 2023-01-13 | Katz Barrett | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,147 | 0.00 | — | 291,853 | — | ↗ |
| 2023-01-10 | Katz Barrett | Officer | S-Sale | D | Common Stock | 47,377 | 35.30 | 1.67M | 0 | — | ↗ |
| 2023-01-09 | Katz Barrett | Officer | M-Exempt | A | Common Stock | 12,623 | 23.03 | 290.7K | 12,623 | — | ↗ |
| 2022-12-21 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 16,326 | 0.00 | — | 44,721 | — | ↗ |
| 2022-12-20 | Meisner Lara | Officer | M-Exempt | A | Common Stock | 600 | 23.03 | 13.8K | 600 | — | ↗ |
| 2022-12-16 | Meisner Lara | Officer | S-Sale | D | Common Stock | 1,297 | 28.44 | 36.9K | 0 | — | ↗ |
| 2022-12-15 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 300 | 0.00 | — | 62,944 | — | ↗ |
| 2022-12-14 | Meisner Lara | Officer | S-Sale | D | Common Stock | 15,656 | 28.12 | 440.2K | 0 | — | ↗ |
| 2022-12-12 | Meisner Lara | Officer | M-Exempt | A | Common Stock | 600 | 23.03 | 13.8K | 600 | — | ↗ |
| 2022-11-15 | Meisner Lara | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,125 | 0.00 | — | 21,875 | — | ↗ |
| 2022-08-17 | Fairmount Healthcare Fund II L.P. | Director | P-Purchase | A | Common Stock | 425,531 | 23.50 | 10.00M | 1,363,764 | — | ↗ |
| 2022-06-21 | Melvin Carrie | Officer | — | D | Stock Option (Right to Buy) | 210,000 | 10.63 | 2.23M | 0 | — | ↗ |
| 2022-06-08 | Moses Jennifer K. | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 12.31 | 153.9K | 12,500 | — | ↗ |
| 2022-06-08 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-08 | Kiselak Tomas | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 0.00 | — | 12,500 | — | ↗ |
| 2022-06-08 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 12.31 | 153.9K | 12,500 | — | ↗ |
| 2022-06-01 | Violin Jonathan | Officer | S-Sale | D | Common Stock | 30,000 | 12.20 | 366.0K | 480,905 | — | ↗ |
| 2022-05-02 | Violin Jonathan | Officer | S-Sale | D | Common Stock | 30,000 | 13.04 | 391.2K | 510,905 | — | ↗ |
| 2022-04-01 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 26,400 | 18.92 | 499.5K | 544,505 | — | ↗ |
| 2022-03-02 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 11,106 | 17.36 | 192.8K | 570,905 | — | ↗ |
| 2022-03-01 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 18,894 | 17.82 | 336.7K | 582,011 | — | ↗ |
| 2022-02-03 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 909 | 19.16 | 17.4K | 600,905 | — | ↗ |
| 2022-02-02 | Violin Jonathan | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 280,000 | 18.51 | 5.18M | 280,000 | — | ↗ |
| 2022-02-02 | Meisner Lara | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 18.51 | 1.67M | 90,000 | — | ↗ |
| 2022-02-02 | Katz Barrett | Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 18.51 | 2.04M | 110,000 | — | ↗ |
| 2022-02-02 | Humer Kristian | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 18.51 | 1.67M | 90,000 | — | ↗ |
| 2022-02-01 | Violin Jonathan | Director / Officer | S-Sale | D | Common Stock | 16,751 | 19.55 | 327.5K | 614,154 | — | ↗ |
| 2021-12-31 | Humer Kristian | Officer | A-Award | A | Stock Option (Right to Buy) | 121,371 | 19.77 | 2.40M | 121,371 | — | ↗ |
| 2021-12-08 | Violin Jonathan | Director / Officer | C-Conversion | A | Common Stock | 627,564 | 0.00 | — | 630,905 | — | ↗ |
| 2021-10-01 | Meisner Lara | Officer | — | D | Stock Option (Right to Buy) | 79,500 | 23.03 | 1.83M | 0 | — | ↗ |
| 2021-09-23 | Frazier Life Sciences Public Fund, L.P. | 10% Owner | P-Purchase | A | Common Stock | 200,000 | 11.00 | 2.20M | 1,505,200 | — | ↗ |
| 2021-09-21 | Fairmount Funds Management LLC | Director / 10% Owner | P-Purchase | A | Common Stock | 909,000 | 11.00 | 10.00M | 938,233 | — | ↗ |
| 2021-08-16 | Frazier Life Sciences Public Fund, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,305,200 | — | ↗ |
| 2021-07-26 | Humer Kristian | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-14 | Moses Jennifer K. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-03 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 16.60 | 207.5K | 12,500 | — | ↗ |
| 2021-06-03 | Kiselak Tomas | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 16.60 | 207.5K | 12,500 | — | ↗ |
| 2021-06-03 | Harwin Peter Evan | Director | A-Award | A | Stock Option (Right to Buy) | 12,500 | 16.60 | 207.5K | 12,500 | — | ↗ |
| 2021-02-04 | TURNER JOSEPH L | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 20.50 | 512.5K | 25,000 | — | ↗ |
| 2021-02-04 | Morris Arlene | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 20.50 | 512.5K | 25,000 | — | ↗ |
| 2021-02-04 | Kiselak Tomas | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 20.50 | 512.5K | 25,000 | — | ↗ |
| 2021-02-04 | Hatfield Jeffrey S. | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 20.50 | 512.5K | 25,000 | — | ↗ |
| 2021-02-04 | Harwin Peter Evan | Director | A-Award | A | Director Stock Option (Right to Buy) | 25,000 | 20.50 | 512.5K | 25,000 | — | ↗ |
| 2021-01-20 | Katz Barrett | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-01-18 | Violin Jonathan | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 800,075 | 23.03 | 18.43M | 800,075 | — | ↗ |
| 2021-01-18 | Rauch Lee M. | — | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 23.03 | 345.5K | 15,000 | — | ↗ |
| 2021-01-18 | Leverone Jason A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 311,785 | 23.03 | 7.18M | 311,785 | — | ↗ |
| 2021-01-18 | Katz Barrett | Officer | A-Award | A | Employee Stock Option (right to buy) | 356,000 | 23.03 | 8.20M | 356,000 | — | ↗ |
| 2021-01-15 | Escolar Diana | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-07 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 410,686 | — | ↗ |
| 2020-11-13 | Logos Global Master Fund LP | 10% Owner | P-Purchase | A | Common Stock | 126,667 | 14.84 | 1.88M | 550,000 | — | ↗ |
| 2020-11-10 | Point72 Asset Management, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 426,162 | — | ↗ |
| 2020-11-09 | Logos Global Master Fund LP | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 1.16 | 116.4K | 6,350,000 | — | ↗ |
| 2020-11-04 | Logos Global Master Fund LP | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 6,000,000 | — | ↗ |
| 2020-10-30 | Fairmount Funds Management LLC | Director | P-Purchase | A | Series A Non-Voting Convertible Preferred Stock | 28,843 | 0.00 | — | 111,192 | — | ↗ |
| 2020-10-27 | Violin Jonathan | Officer | J-Other | A | Employee Stock Option (Right to Buy) | 4,338,079 | 0.01 | 43.4K | 4,338,079 | — | ↗ |
| 2020-10-27 | Kiselak Tomas | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 0.52 | 12.5K | 24,000 | — | ↗ |
| 2020-10-27 | Harwin Peter Evan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-10-27 | Fairmount Funds Management LLC | Director | J-Other | A | Common Stock | 438,502 | 0.00 | — | 438,502 | — | ↗ |
| 2020-10-15 | Marshall William Stuart | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-09-14 | Rauch Lee M. | Director / Officer | A-Award | A | Stock Option (right to buy) | 900,000 | 0.91 | 817.8K | 900,000 | — | ↗ |
| 2020-09-13 | Rauch Lee M. | Director / Officer | A-Award | A | Stock Option (right to buy) | 900,000 | 0.91 | 817.8K | 900,000 | — | ↗ |
| 2020-06-24 | Rauch Lee M. | Officer | — | D | Stock Option (right to buy) | 530,733 | 0.94 | 498.7K | 0 | — | ↗ |
| 2020-05-21 | TURNER JOSEPH L | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-05-21 | Morris Arlene | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-05-21 | KOCH KEVIN | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-05-21 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-05-21 | Hatfield Jeffrey S. | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-05-21 | Bowden Christopher | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 0.63 | 15.0K | 24,000 | — | ↗ |
| 2020-03-13 | Leverone Jason A. | Officer | M-Exempt | A | Common Stock | 11,249 | 0.57 | 6.4K | 48,829 | — | ↗ |
| 2020-02-21 | Marshall William Stuart | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-12 | Marshall William Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 464,000 | 0.80 | 368.9K | 464,000 | — | ↗ |
| 2020-02-12 | Leverone Jason A. | Officer | A-Award | A | Stock Option (right to buy) | 185,000 | 0.80 | 147.1K | 185,000 | — | ↗ |
| 2020-02-12 | Escolar Diana | Officer | A-Award | A | Stock Option (right to buy) | 270,000 | 0.80 | 214.7K | 270,000 | — | ↗ |
| 2019-12-31 | Marshall William Stuart | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-10 | Escolar Diana | Officer | — | D | Stock Option (right to buy) | 25,000 | 2.96 | 74.0K | 0 | — | ↗ |
| 2019-08-23 | Leverone Jason A. | Officer | M-Exempt | D | Stock Option (right to buy) | 3,093 | 0.57 | 1.8K | 0 | — | ↗ |
| 2019-06-19 | TURNER JOSEPH L | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-06-19 | Morris Arlene | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-06-19 | KOCH KEVIN | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-06-19 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-06-19 | Hatfield Jeffrey S. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-06-19 | Bowden Christopher | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.36 | 28.3K | 12,000 | — | ↗ |
| 2019-04-03 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 10,106 | 2.99 | 30.2K | 10,106 | — | ↗ |
| 2019-02-06 | RUBIN PAUL D | Officer | A-Award | A | Stock Option (right to buy) | 87,000 | 2.96 | 257.5K | 87,000 | — | ↗ |
| 2019-02-06 | Marshall William Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 232,000 | 2.96 | 686.7K | 232,000 | — | ↗ |
| 2019-02-06 | Levy Adam Scott | Officer | A-Award | A | Stock Option (right to buy) | 74,000 | 2.96 | 219.0K | 74,000 | — | ↗ |
| 2019-02-06 | Leverone Jason A. | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 2.96 | 222.0K | 75,000 | — | ↗ |
| 2018-10-11 | Hughes Thomas E. | Director | P-Purchase | A | Common Stock | 10,000 | 4.77 | 47.7K | 12,827 | — | ↗ |
| 2018-08-21 | Marshall William Stuart | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Levy Adam Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-21 | Leverone Jason A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-07 | Leverone Jason A. | Officer | M-Exempt | A | Common Stock | 29,530 | 0.57 | 16.8K | 30,737 | — | ↗ |
| 2018-06-27 | TURNER JOSEPH L | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | Morris Arlene | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | KOCH KEVIN | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | Hatfield Jeffrey S. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | Bowden Christopher | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-06-27 | Booth Bruce | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.46 | 77.5K | 12,000 | — | ↗ |
| 2018-02-21 | Marshall William Stuart | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-21 | Levy Adam Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-21 | Leverone Jason A. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-02-13 | Marshall William Stuart | Director / Officer | M-Exempt | A | Common Stock | 115,818 | 0.57 | 66.0K | 265,646 | — | ↗ |
| 2018-02-13 | Levy Adam Scott | Officer | P-Purchase | A | Common Stock | 9,090 | 5.50 | 50.0K | 10,540 | — | ↗ |
| 2018-02-13 | Booth Bruce | Director | P-Purchase | A | Common Stock | 545,454 | 5.50 | 3.00M | 1,351,090 | — | ↗ |
| 2018-01-31 | RUBIN PAUL D | Officer | A-Award | A | Stock Option (right to buy) | 85,000 | 7.50 | 637.5K | 85,000 | — | ↗ |
| 2018-01-31 | Marshall William Stuart | Director / Officer | A-Award | A | Stock Option (right to buy) | 245,000 | 7.50 | 1.84M | 245,000 | — | ↗ |
| 2018-01-31 | Levy Adam Scott | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 7.50 | 600.0K | 80,000 | — | ↗ |
| 2018-01-31 | Leverone Jason A. | Officer | A-Award | A | Stock Option (right to buy) | 75,000 | 7.50 | 562.5K | 75,000 | — | ↗ |
| 2018-01-03 | Morris Arlene | Director | — | D | Stock Option (right to buy) | 24,000 | 9.72 | 233.3K | 0 | — | ↗ |
| 2018-01-03 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 3,426 | 9.72 | 33.3K | 3,426 | — | ↗ |
| 2018-01-03 | Booth Bruce | Director | A-Award | A | Stock Option (right to buy) | 10,191 | 9.72 | 99.1K | 10,191 | — | ↗ |
| 2017-12-20 | Hughes Thomas E. | Director | S-Sale | D | Common Stock | 12,000 | 8.00 | 96.0K | 2,827 | — | ↗ |
| 2017-08-21 | Marshall William Stuart | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-21 | Levy Adam Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-08-10 | Hatfield Jeffrey S. | Director | — | D | Stock Option (right to buy) | 24,000 | 11.12 | 266.9K | 0 | — | ↗ |
| 2017-08-10 | Bowden Christopher | Director | — | D | Stock Option (right to buy) | 24,000 | 11.12 | 266.9K | 0 | — | ↗ |
| 2017-06-28 | TURNER JOSEPH L | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-28 | LEFKOFF KYLE | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-28 | KOCH KEVIN | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-28 | Hughes Thomas E. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-28 | Creecy John W | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-28 | Booth Bruce | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 12.06 | 144.7K | 12,000 | — | ↗ |
| 2017-06-22 | Levy Adam Scott | Officer | P-Purchase | A | Common Stock | 200 | 7.55 | 1.5K | 200 | — | ↗ |
| 2017-03-24 | Hughes Thomas E. | Director | A-Award | A | Common Stock | 778 | 0.00 | — | 14,840 | — | ↗ |
| 2017-03-24 | Booth Bruce | Director | A-Award | A | Stock Option (right to buy) | 6,844 | 11.80 | 80.8K | 6,844 | — | ↗ |
| 2017-03-10 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 3,300 | 14.31 | 47.2K | 463,473 | — | ↗ |
| 2017-03-09 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 2,500 | 14.38 | 36.0K | 466,773 | — | ↗ |
| 2017-03-08 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 5,000 | 14.70 | 73.5K | 469,273 | — | ↗ |
| 2017-03-06 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 9,392 | 15.71 | 147.6K | 474,881 | — | ↗ |
| 2017-02-28 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 2,258 | 13.54 | 30.6K | 484,273 | — | ↗ |
| 2017-02-27 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 1,500 | 13.79 | 20.7K | 486,531 | — | ↗ |
| 2017-02-24 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 6,500 | 14.04 | 91.3K | 488,031 | — | ↗ |
| 2017-02-23 | LEFKOFF KYLE | Director | S-Sale | D | Common Stock | 1,800 | 13.65 | 24.6K | 494,531 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-23.6K
Shares Outstanding
84.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Stephen Mahoney, Chief Executive Officer | 700.0K | — | 1.06M | 4.38M | 630.0K | 6.4K | 6.78M | 80.28% | ↗ |
| 2 | 2025 | Dr. Radhika Tripuraneni | 430.6K | 50.0K | — | 3.34M | 253.5K | 4.9K | 4.08M | 81.89% | ↗ |
| 3 | 2025 | Thomas Beetham, Chief Operating Officer | 545.0K | — | 542.3K | 2.25M | 408.8K | 19.2K | 3.76M | 74.13% | ↗ |
| 4 | 2025 | Seth Harmon, Chief Financial Officer | 480.0K | — | 361.2K | 1.50M | 288.0K | 17.7K | 2.64M | 70.27% | ↗ |
| 5 | 2025 | Jennifer Tousignant, Chief Legal Officer | 469.9K | 50.0K | 298.0K | 1.23M | 281.9K | 18.1K | 2.35M | 65.14% | ↗ |
| 6 | 2024 | Jennifer Tousignant, Chief Legal Officer | 400.6K | 150.0K | — | 4.12M | 234.0K | 9.3K | 4.91M | 83.83% | ↗ |
| 7 | 2024 | Dr. Barrett Katz, Former Chief Medical Officer | 5.7K | — | — | 1.06M | — | 1.09M | 2.16M | 49.25% | ↗ |
| 8 | 2024 | Dr. Thomas Ciulla, Chief Medical Officer | 509.3K | 144.0K | — | 674.5K | 264.8K | 18.0K | 1.61M | 41.88% | ↗ |
| 9 | 2024 | Stephen Mahoney, Chief Executive Officer | 650.0K | — | — | — | 464.8K | 2.7K | 1.12M | 0.00% | ↗ |
| 10 | 2024 | Thomas Beetham, Chief Operating Officer | 500.0K | — | — | — | 292.5K | 17.0K | 809.5K | 0.00% | ↗ |
| 11 | 2024 | Seth Harmon, Senior Vice President, Finance and Accounting | 419.6K | 123.0K | — | — | 218.2K | 9.9K | 770.7K | 0.00% | ↗ |
| 12 | 2024 | Seth Harmon, Chief Financial Officer | 419.6K | 123.0K | — | — | 218.2K | 9.9K | 770.7K | 0.00% | ↗ |
| 13 | 2023 | Scott Myers Former President, Chief Executive Officer and Director | 549.5K | — | 8.95M | 26.79M | — | 122.4K | 36.41M | 98.15% | ↗ |
| 14 | 2023 | Stephen Mahoney, Chief Executive Officer | 112.8K | 63.8K | — | 12.30M | — | 184.00 | 12.48M | 98.58% | ↗ |
| 15 | 2023 | Stephen Mahoney President, Chief Executive Officer and Director | 112.8K | 63.8K | — | 12.30M | — | 184.00 | 12.48M | 98.58% | ↗ |
| 16 | 2023 | Dr. Thomas Ciulla, Chief Medical Officer | 414.0K | 235.1K | — | 10.00M | — | 1.8K | 10.65M | 93.89% | ↗ |
| 17 | 2023 | Seth Harmon, Chief Financial Officer | 241.4K | 372.2K | — | 5.93M | — | 4.3K | 6.55M | 90.56% | ↗ |
| 18 | 2023 | Seth Harmon Senior Vice President of Finance and Accounting | 241.4K | 372.2K | — | 5.93M | — | 4.3K | 6.55M | 90.56% | ↗ |
| 19 | 2023 | Seth Harmon, Senior Vice President, Finance and Accounting | 241.4K | 372.2K | — | 5.93M | — | 4.3K | 6.55M | 90.56% | ↗ |
| 20 | 2023 | Thomas Beetham, Chief Operating Officer | 86.8K | 40.1K | — | 4.63M | — | 184.00 | 4.76M | 97.33% | ↗ |
| 21 | 2023 | Thomas Beetham Chief Operating Officer | 86.8K | 40.1K | — | 4.63M | — | 184.00 | 4.76M | 97.33% | ↗ |
| 22 | 2023 | Dr. Barrett Katz, Former Chief Medical Officer | 502.2K | — | — | 2.76M | — | 9.9K | 3.28M | 84.37% | ↗ |
| 23 | 2023 | Jonathan Violin, Ph.D. Former President, Chief Executive Officer and Director | 59.2K | — | — | 1.59M | — | 564.7K | 2.21M | 71.78% | ↗ |
| 24 | 2022 | Jonathan Violin, Ph.D. Former President, Chief Executive Officer and Director | 601.2K | 288.6K | — | 3.75M | — | 2.3K | 4.65M | 80.80% | ↗ |
| 25 | 2022 | Barrett Katz, M.D. Chief Medical Officer | 487.6K | 136.5K | — | 1.48M | — | 11.5K | 2.11M | 69.89% | ↗ |
| 26 | 2022 | Dr. Barrett Katz, Former Chief Medical Officer | 487.6K | 136.5K | — | 1.48M | — | 11.5K | 2.11M | 69.89% | ↗ |
| 27 | 2022 | Kristian Humer Chief Financial and Business Officer | 561.8K | 252.8K | — | 1.21M | — | 2.3K | 2.02M | 59.63% | ↗ |
| 28 | 2021 | Jonathan Violin, Ph.D. President, Chief Executive Officer and Director | 567.0K | 408.2K | — | 16.42M | — | 9.0K | 17.41M | 94.35% | ↗ |
| 29 | 2021 | Jonathan Violin, Ph.D. Former President, Chief Executive Officer and Director | 567.0K | 408.2K | — | 16.42M | — | 9.0K | 17.41M | 94.35% | ↗ |
| 30 | 2021 | Barrett Katz Chief Medical Officer | 440.8K | 404.8K | — | 7.31M | — | 13.3K | 8.17M | 89.48% | ↗ |
| 31 | 2021 | Barrett Katz, M.D. Chief Medical Officer | 440.8K | 404.8K | — | 7.31M | — | 13.3K | 8.17M | 89.48% | ↗ |
| 32 | 2021 | Kristian Humer Chief Financial and Business Officer | 230.9K | 686.2K | — | 6.79M | — | 1.1K | 7.71M | 88.09% | ↗ |
| 33 | 2021 | Lee Rauch Former President and Chief Executive Officer and Director | 22.5K | 541.0K | — | 307.9K | — | 907.6K | 1.78M | 17.31% | ↗ |
| 34 | 2020 | William S. Marshall, Ph.D. Former President and Chief Executive Officer | 424.8K | — | — | 585.1K | — | 1.18M | 2.19M | 26.76% | ↗ |
| 35 | 2020 | Lee Rauch Former President and Chief Executive Officer and Director | 256.4K | 270.5K | — | 1.14M | — | 3.8K | 1.67M | 68.23% | ↗ |
| 36 | 2020 | Lee Rauch Former President, Chief Executive Officer and Director | 256.4K | 270.5K | — | 1.14M | — | 3.8K | 1.67M | 68.23% | ↗ |
| 37 | 2020 | Diana Escolar, M.D. Former Chief Medical Officer | 417.5K | 277.8K | — | 164.5K | — | 5.9K | 865.6K | 19.00% | ↗ |
| 38 | 2020 | Jason A. Leverone Chief Financial Officer, Treasurer, and Secretary | 365.7K | — | — | 112.7K | — | 4.7K | 483.0K | 23.34% | ↗ |
| 39 | 2019 | William S. Marshall, Ph.D. Former President and Chief Executive Officer | 521.0K | — | — | 551.3K | — | 3.6K | 1.08M | 51.24% | ↗ |
| 40 | 2019 | William S. Marshall, Ph.D. President and Chief Executive Officer | 521.0K | — | — | 551.3K | — | — | 1.07M | 51.41% | ↗ |
| 41 | 2019 | Paul D. Rubin, M.D. Former Executive Vice President, Research and Development | 426.0K | — | — | 206.7K | — | — | 632.7K | 32.67% | ↗ |
| 42 | 2019 | Diana Escolar, M.D. Former Chief Medical Officer | 372.6K | 111.8K | — | 59.4K | — | 6.2K | 550.0K | 10.80% | ↗ |
| 43 | 2019 | Diana Escolar, M.D. Chief Medical Officer | 372.6K | 111.8K | — | 59.4K | — | — | 543.8K | 10.92% | ↗ |
| 44 | 2019 | Jason A. Leverone Chief Financial Officer, Treasurer, and Secretary | 355.0K | — | — | 178.2K | — | 4.6K | 537.8K | 33.14% | ↗ |
| 45 | 2019 | Jason A. Leverone Chief Financial Officer | 355.0K | — | — | 178.2K | — | — | 533.2K | 33.42% | ↗ |
| 46 | 2018 | William S. Marshall, Ph.D. President and Chief Executive Officer | 490.0K | — | — | 1.35M | 147.0K | — | 1.99M | 67.94% | ↗ |
| 47 | 2018 | Paul D. Rubin, M.D. Former Executive Vice President, Research and Development | 410.0K | — | — | 468.4K | 98.4K | — | 976.8K | 47.95% | ↗ |
| 48 | 2018 | Jason A. Leverone Chief Financial Officer | 340.0K | — | — | 413.3K | 71.4K | — | 824.7K | 50.11% | ↗ |
| 49 | 2017 | William President S. and | 400.0K | 180.0K | — | 1.61M | — | — | 2.19M | 73.51% | ↗ |
| 50 | 2017 | Adam Officer S. Chief | 395.0K | 142.2K | — | 704.1K | — | — | 1.24M | 56.72% | ↗ |
| 51 | 2017 | Marshall, Chief Ph.D. Executive | 300.0K | 108.0K | — | 704.1K | — | — | 1.11M | 63.31% | ↗ |
| 52 | 2017 | Levy Business Paul Officer D. Executive Rubin, Vice M.D. President, Samuel Research D. and Riccitelli Development | 56.5K | 144.5K | — | — | — | 499.5K | 700.5K | 0.00% | ↗ |
| 53 | 2016 | Adam Officer S. Chief | 124.4K | 33.6K | — | 809.6K | — | — | 967.6K | 83.68% | ↗ |
| 54 | 2016 | Samuel D. Riccitelli Chief Executive Officer and President | 450.0K | 135.0K | 102.0K | — | — | — | 687.0K | 14.85% | ↗ |
| 55 | 2016 | Levy Business Paul Officer D. Executive Rubin, Vice M.D. President, Samuel Research D. and Riccitelli Development | 450.0K | 135.0K | 102.0K | — | — | — | 687.0K | 14.85% | ↗ |
| 56 | 2016 | William President S. and | 347.1K | 200.1K | — | 109.8K | — | — | 656.9K | 16.71% | ↗ |
| 57 | 2016 | Tamara A. Seymour Chief Financial Officer | 350.0K | 105.0K | 51.0K | — | — | — | 506.0K | 10.08% | ↗ |
| 58 | 2016 | Marshall, Chief Ph.D. Executive | 187.5K | 150.0K | — | 113.6K | — | 20.4K | 471.5K | 24.10% | ↗ |
| 59 | 2015 | Samuel D. Riccitelli Chief Executive Officer and President | 450.0K | 135.0K | — | — | — | — | 585.0K | 0.00% | ↗ |
| 60 | 2015 | Tamara A. Seymour Chief Financial Officer | 350.0K | 105.0K | — | 53.1K | — | — | 508.1K | 10.45% | ↗ |
| 61 | 2014 | Samuel D. Riccitelli Chief Executive Officer | 450.0K | 90.0K | 7.46M | — | — | 24.2K | 8.02M | 92.96% | ↗ |
| 62 | 2014 | Samuel D. Riccitelli Chief Executive Officer and President | 450.0K | 90.0K | 7.46M | — | — | 24.2K | 8.02M | 92.96% | ↗ |
| 63 | 2014 | Tamara A. Seymour Chief Financial Officer | 144.7K | 43.4K | 468.3K | — | — | 1.4K | 657.8K | 71.19% | ↗ |
| 64 | 2013 | Samuel D. Riccitelli Chief Executive Officer | 450.0K | — | — | — | — | 114.9K | 564.9K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 1M | male |
| Thomas W. Beetham | Chief Operating Officer | 973.0K | male |
| Radhika Tripuraneni | Chief Medical Officer | 840.7K | — |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | 820.0K | female |
| Seth Harmon | Chief Financial Officer | 785.7K | male |
| Anthony Casciano | Chief Commercial Officer | — | male |
| Vahe Bedian | Co-Founder & Scientific Advisor | — | male |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | — | — |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | — | — |
| Melissa Manno | Chief Human Resources Officer | — | female |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VRDN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
